发布: 2019年02月20日第9卷第4期 DOI: 10.21769/BioProtoc.3167 浏览次数: 6047
评审: Pengpeng LiYuanfan ZhangAnonymous reviewer(s)
Abstract
Mesenchymal stem cells (MSCs) have attracted significant attention as potential therapeutic cells to treat various diseases ranging from tissue injuries, graft versus host disease, degenerative diseases and cancer. Since the initial discovery of MSCs in the bone marrow cells, MSCs have been successfully isolated from various adult and neo-natal tissues, albeit the procedures are often coupled with difficulties in harvesting tissue and produce low yield of cells, requiring extensive expansion in vitro. Here, we explored extra-ocular muscle tissues obtained from patients as a novel source of MSCs which express characteristic cell surface markers of MSCs and show multilineage differentiation potential with high proliferation capacity.
Keywords: Mesenchymal stem cells (间充质干细胞)Background
Mesenchymal stem cells (MSCs) were originally identified as plastic adherent, fibroblastic cells derived from bone marrow and showed multi-lineage differentiation potential (Friedenstein et al., 1974a and 1974b). Over the years, MSCs have been implicated to play a role in a wide range of biological processes such as hematopoiesis (Friedenstein et al., 1974a), immune-modulation (Klyushnenkova et al., 2005; Crop et al., 2010), tissue repair, angiogenesis, tumorigenesis (Yagi and Kitagawa, 2013) and chemoresistance (Kumar et al., 2017). MSCs possess a vast secretome and have been heralded as factories of extracellular vesicles and “injury drug store” (Caplan and Correa, 2011) for their ability to produce a myriad number of growth factors and cytokines. The secreted factors of MSCs were found to have roles in tissue repair of renal (Grange et al., 2014; Zhang et al., 2014), neural (Koc et al., 2002; Zappia et al., 2005), liver (Li et al., 2013), lung (Lee et al., 2012), myocardial (Timmers et al., 2008; Bian et al., 2014) as well as ischemic injuries (Zhang et al., 2012). Therefore, MSCs are being explored as a therapeutic option for ameliorating various diseases such as myocardial infarction, respiratory disorders, Crohn’s disease, graft versus host disease, diabetes, bone disorders, as well as liver cirrhosis (Uccelli et al., 2008; Battiwalla and Hematti, 2009; Luk et al., 2015).
Cells with similar properties of bone marrow derived MSCs (BM-MSCs) have since been isolated from placenta, amniotic fluid (Tsai et al., 2004), umbilical cord blood (Bieback et al., 2004), mobilized peripheral blood, adipose tissue (Kim et al., 2013), connective tissue, skeletal muscle (Young et al., 2001), dental (Gronthos et al., 2000), fetal tissue (Shin et al., 2009) and extra-ocular muscle tissue (Mawrie et al., 2016). This protocol explores extraocular muscle as a novel source of MSCs which is generally excised and discarded during strabismus correction surgery. Strabismus surgery is the third most common eye surgery in US with up to 1.2 million cases per year. The incised tissue is discarded after procedure, which can be used as a source of MSCs. Extraocular muscles are unaffected during Duchenne's muscular dystrophy (Kaminski et al., 1992; Khurana et al., 1995) and contain 15 times more side population stem cells than skeletal muscle (Pacheco-Pinedo et al., 2009). The extraocular muscle derived MSCs (EOM-MSCs) expressed CD73, CD90 and CD105 (Mawrie et al., 2016) which are characteristic cell surface markers for MSCs (Dominici et al., 2006) and could differentiate into all the three meseodermal lineages (Mawrie et al., 2016). Moreover, EOM-MSCs are relatively easy to isolate, have high proliferation capacity, neuroectodermal differentiation potential and might be a good candidate for stem cell based therapy for treating neurodegenerative disorders (Mawrie et al., 2016).
Materials and Reagents
S. No. | Marker | Antibody | Manufacturer | Dilution | Amount added per 50 μl of FACS buffer |
1. | CD29 | Anti-human CD29 PE | BD Biosciences, catalog number: 555443 | 1:100 | 0.5 μl |
2. | CD34 | Anti-human CD34 FITC | Thermo Fisher Scientific, catalog number: CD3458101 | 1:100 | 0.5 μl |
3. | CD44 | Anti-human CD44 FITC | BD Biosciences, catalog number: 555478 | 1:100 | 0.5 μl |
4. | CD49e | Anti-human CD49e PE | BD Biosciences, catalog number: 555617 | 1:100 | 0.5 μl |
5. | CD73 | Anti-human CD73 PE | BD Biosciences, catalog number: 550257 | 1:100 | 0.5 μl |
6. | CD90 | Anti-human CD90 FITC | BD Biosciences, catalog number: 555595 | 1:100 | 0.5 μl |
7. | CD105 | Anti-human CD105 PE | BD Biosciences, catalog number: 560839 | 1:100 | 0.5 μl |
8. | HLA1 | Anti-human HLA1 FITC | BD Biosciences, catalog number: 555552 | 1:100 | 0.5 μl |
9. | Isotype control | Anti-mouse IgG1 PE | BD, catalog number: 556561 | 1:100 | 0.5 μl |
10. | Isotype control | Anti-mouse IgG1 FITC | BD, catalog number: 554109 | 1:100 | 0.5 μl |
Equipment
*Note: These items can be ordered from any qualified company.
Software
Procedure
文章信息
版权信息
© 2019 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Sharma, A., Mawrie, D., Magdalene, D. and Jaganathan, B. G. (2019). Isolation of Multipotent Mesenchymal Stem Cells from Human Extraocular Muscle Tissue. Bio-protocol 9(4): e3167. DOI: 10.21769/BioProtoc.3167.
分类
干细胞 > 成体干细胞 > 间充质干细胞
细胞生物学 > 细胞分离和培养 > 细胞分化
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link